Close Menu

non-small cell lung cancer

The randomized trial will assess the glutaminase inhibitor plus standard-of-care versus standard-of-care alone in patients with KEAP1- or NRF2-mutated tumors.

In two studies at ESMO, researchers demonstrated the ability of combined biomarker approaches to predict the efficacy of immune checkpoint inhibitors.

Phase I data at ESMO suggested that the experimental drug may be particularly effective in KRAS G12C-mutated lung and colon cancers.

The data may result in another option for patients in the crowded first-line ALK-positive lung cancer market, though progression-free survival data are not yet mature.

 

AstraZeneca's EGFR-inhibitor has now demonstrated an 'overwhelming' disease-free survival and CNS recurrence benefit, but overall survival benefit remains unknown.

The European Commission will now consider CHMP's opinion and decide whether to approve the regimen as a first-line option for metastatic NSCLC patients without EGFR or ALK alterations.

The tests will be developed to identify NSCLC patients with ALK fusions and EGFR Exon20 insertion mutations who respond to mobocertinib or brigatinib.

Once finalized, lung cancer patients in England can receive the drug for two years after they've received chemotherapy and if their tumors express PD-L1.

The MET inhibitor OMO-1 will be studied with Allist's EGFR inhibitor furmonertinib in patients with MET-positive, EGFR-mutated cancers.

NICE is reversing its earlier negative recommendation for the lung cancer drug after AstraZeneca agreed to provide it at a discount.

Pages